Shares of Syros Pharmaceuticals (NASDAQ:SYRS) have earned an average rating of “Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $21.13.
Several research analysts have recently issued reports on the company. BidaskClub upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. HC Wainwright restated a “hold” rating and issued a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, March 14th. Wedbush restated an “outperform” rating and issued a $13.00 price target (up from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. Zacks Investment Research lowered Syros Pharmaceuticals from a “buy” rating to a “hold” rating and set a $12.00 price target on the stock. in a research report on Saturday, January 20th. Finally, Oppenheimer set a $28.00 price target on Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 8th.
Shares of SYRS stock traded down $0.34 on Friday, reaching $12.45. The company’s stock had a trading volume of 115,947 shares, compared to its average volume of 203,684. Syros Pharmaceuticals has a 52-week low of $6.30 and a 52-week high of $24.38. The company has a market cap of $411.76, a price-to-earnings ratio of -5.87 and a beta of -2.26.
In other Syros Pharmaceuticals news, Director Srinivas Akkaraju acquired 209,424 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The shares were acquired at an average price of $9.55 per share, with a total value of $1,999,999.20. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 33.60% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in Syros Pharmaceuticals by 17.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 35,329 shares of the company’s stock worth $520,000 after buying an additional 5,305 shares during the period. New York State Common Retirement Fund raised its stake in Syros Pharmaceuticals by 167.9% during the 2nd quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock worth $216,000 after buying an additional 8,399 shares during the period. Russell Investments Group Ltd. acquired a new stake in Syros Pharmaceuticals during the 3rd quarter worth $133,000. Two Sigma Investments LP raised its stake in Syros Pharmaceuticals by 80.3% during the 4th quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock worth $206,000 after buying an additional 9,439 shares during the period. Finally, Ark Investment Management LLC raised its stake in Syros Pharmaceuticals by 114.7% during the 2nd quarter. Ark Investment Management LLC now owns 17,705 shares of the company’s stock worth $285,000 after buying an additional 9,460 shares during the period. 49.33% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Syros Pharmaceuticals (SYRS) Given Consensus Rating of “Buy” by Brokerages” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3297462/syros-pharmaceuticals-syrs-given-consensus-rating-of-buy-by-brokerages.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.